Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma

Blood

Volumn 125, Issue 24, 2015, Pages 3756-3759

  Sawyer, Jeffrey R ^a,b,c   Tian, Erming ^b   Heuck, Christoph J ^b   Johann, Donald J ^b   Epstein, Joshua ^b   Swanson, Charles M ^a   Lukacs, Janet L ^a   Binz, Regina Lichti ^a   Johnson, Marian ^a   Sammartino, Gael ^a   Zangari, Maurizio ^b   Davies, Faith E ^b   Van Rhee, Frits ^b   Morgan, Gareth J ^b   Barlogie, Bart ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Cytogenetics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DNA; MYC PROTEIN;

ARTICLE; BLOOD CULTURE; CENTROMERE; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; COPY NUMBER ABERRATION; DNA METHYLATION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HETEROCHROMATIN; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; SPECTRAL KARYOTYPING; CHROMOSOME 1; GENE TRANSLOCATION; GENETIC EPIGENESIS; GENETICS;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; DNA METHYLATION; EPIGENESIS, GENETIC; GENE DOSAGE; HUMANS; MULTIPLE MYELOMA; TRANSLOCATION, GENETIC;

EID: 84931292225     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-632075     Document Type: Article

References (25)

1. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348.
2. Chng WJ, Dispenzieri A, Chim CS, et al International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-277.
3. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
4. Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. JClinOncol.2012;30(16): 1949-1952.
5. Boyd KD, Ross FM, Chiecchio L, et al NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on cosegregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349-355.
6. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724-1732.
7. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006; 108(5):1733-1743.
8. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998; 91(5):1732-1741.
9. Sawyer JR, Tricot G, Lukacs JL, et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer. 2005; 42(1):95-106.
10. Fournier A, Florin A, Lefebvre C, Solly F, Leroux D, Callanan MB. Genetics and epigenetics of 1q rearrangements in hematological malignancies. Cytogenet Genome Res. 2007;118(2-4):320-327.
11. Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res. 2010;70(17):6934-6944.
12. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117(2):553-562.
13. Heuck CJ, Mehta J, Bhagat T, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013;190(6): 2966-2975.
14. Bollati V, Fabris S, Pegoragro V, et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis. 2009; 30(8):1330-1335.
15. Aoki Y, Nojima M, Suzuki H, et al. Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. Genome Med. 2012;4(12):101.
16. Viegas-Péquignot E, Dutrillaux B. Segmentation of human chromosomes induced by 5-ACR (5-azacytidine). Hum Genet. 1976;34(3):247-254.
17. Schmid M, Haaf T, Grunert D. 5-Azacytidine-induced undercondensations in human chromosomes. Hum Genet. 1984;67(3):257-263.
18. Kokalj-Vokac N, Almeida A, Viegas-Péquignot E, Jeanpierre M, Malfoy B, Dutrillaux B. Specific induction of uncoiling and recombination by azacytidine in classical satellite-containing constitutive heterochromatin. Cytogenet Cell Genet. 1993;63(1):11-15.
19. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol Ther. 1995;65(1): 19-46.
20. Prada D, Gonzalez R, Sanchez L, et al. Satellite 2 demethylation induced by 5-azacytidine is associated with missegregation of chromosomes 1 and 16 in human somatic cells. Mutation Res. 2012;729(1-2):100-105.
21. Yunis JJ, Sawyer JR, Ball DW. The characterization of high-resolution G-banded chromosomes of man. Chromosoma. 1978;67(4): 293-307.
22. Sawyer JR, Tian E, Thomas E, et al. Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon. Br J Haematol. 2009;147(4):484-494.
23. Sawyer JR, Tian E, Heuck CJ, et al. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014;123(16):2504-2512.
24. Jenner MW, Leone PE, Walker BA, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9): 3291-3300.
25. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22(1):9-20.